Transparency

Transparency creates trust

Patients benefit from close cooperation between healthcare professionals and the pharmaceutical industry, because this allows for therapies that are already available to be improved or for new and innovative medicinal products to be developed, so that many diseases can be treated and healed. For the general public to understand what happens between healthcare professionals and healthcare organisations (doctors, hospitals, etc.) and the pharmaceutical industry, the pharmaceutical companies disclose on their websites what non-cash benefits they provide to whom and for which purpose. This initiative helps to increase public understanding for this cooperation, the trust in joint efforts made by doctors and hospitals as well as the pharmaceutical industry is strengthened
(http://www.transparenz-schafft-vertrauen.at/).

As a member of the Austrian Biosimilars Association, Astro Pharma is committed to the association rules of Medicines for Europe, the European association of generics and biosimilar suppliers. According to these association rules, Astro Pharma is subject to a disclosure obligation. Astro Pharma is obliged to disclose all non-cash benefits provided to doctors and other healthcare professionals and healthcare organisations and patient organisations. In item 7.1. (Disclosing Transfers of Value), the association rules of Medicines for Europe provide for disclosure of non-cash benefits resulting from the cooperation of pharmaceutical companies with healthcare professionals and healthcare organisations (doctors, hospitals, etc.). The same item also governs the publication of cooperation with patient organisations.

Disclosure

1. Disclosure 2018

healthcare professionals, healthcare organisations and patient organisations
Disclosure 2018


2. Disclosure 2017

healthcare professionals and healthcare organisations
Disclosure 2017

Patient organisations
In 2017, there was no cooperation with patient organisations.

Methodological note

Under item 7.2. (Company’s Methodological Note) of the association rules of Medicines for Europe, pharmaceutical companies are required to publish a methodological note, together with the disclosure, indicating the method according to which the disclosure is effected.

Methodological Note 2018

Methodological Note 2017